“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Associated equity: InMed Pharmaceuticals
Edison Investment Research is terminating coverage on InMed Pharmaceuticals. Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Previously published reports can still be accessed via our website.
InMed Pharmaceuticals — 14 videos in collection
InMed Pharmaceuticals is a global leader in the manufacture and development of rare cannabinoids. Together with their recently acquired subsidiary, BayMedica, they have unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness.
In this video series, we’ll be introducing the BayMedica team, discussing their impressive careers and experience in the industry and what excites them about the InMed/BayMedica acquisition. Today’s video highlights Phil Barr, VP of Discovery Research.
Get access to the very latest content matched to your personal investment style.
